LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Начало・Списък с акции・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Отворен

СекторЗдравеопазване

2.69 -0.74

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.66

Максимум

2.69

Ключови измерители
By Trading Economics
Приходи	4.1M -5.7M
Служители	34
EBITDA	3.1M -6.8M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+640.74% upside

Дивиденти
By Dow Jones
Следващи печалби	26.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-122M 267M
Предишно отваряне	3.43
Предишно затваряне	2.69

Настроения в новините

By Acuity

91%

325 / 345 Класиране в Healthcare

Anavex Life Sciences Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.05.2026 г., 23:46 ч. UTC

Пазарно говорене

Pullback in Oil Prices Could Temper Inflation Expectations -- Market Talk

24.05.2026 г., 23:45 ч. UTC

Пазарно говорене

Gold, Silver Rise on Hopes for U.S.-Iran Deal -- Market Talk

24.05.2026 г., 23:42 ч. UTC

Пазарно говорене

Mineral Resources Bull More Positive Post Site Visit -- Market Talk

24.05.2026 г., 23:34 ч. UTC

Пазарно говорене

Oil Falls Amid Prospects for Reopening of Strait of Hormuz -- Market Talk

24.05.2026 г., 23:11 ч. UTC

Пазарно говорене

RBNZ Likely to Stand Pat But Watch for Dissent -- Market Talk

24.05.2026 г., 22:26 ч. UTC

Придобивния, сливания и поглъщания

Beach Energy: La Bella 2 Will No Longer Be Drilled as Part of Equinox Campaign

24.05.2026 г., 22:25 ч. UTC

Придобивния, сливания и поглъщания

Beach Energy: Implied Transaction Value of Around A$130 Million After Tax

24.05.2026 г., 22:25 ч. UTC

Придобивния, сливания и поглъщания

Beach Energy: Royalty Payments Likely to Total Around A$140 Million Based on Resource Booking

24.05.2026 г., 22:24 ч. UTC

Придобивния, сливания и поглъщания

Beach Energy to Get Production Royalty of A$3.75/GJ in Deal

24.05.2026 г., 22:24 ч. UTC

Придобивния, сливания и поглъщания

Beach Energy to Get A$70 Million Cash Proceeds When Deal Completes

24.05.2026 г., 22:23 ч. UTC

Придобивния, сливания и поглъщания

Beach Energy Says Deal Includes Artisan Natural-Gas Discovery

24.05.2026 г., 22:23 ч. UTC

Придобивния, сливания и поглъщания

Beach Energy Sells 60% Operated Interest in VIC/L35 Block in Otway Basin

24.05.2026 г., 22:11 ч. UTC

Пазарно говорене

Oil Price Unlikely to Return to Pre-Conflict Levels This Year -- Market Talk

24.05.2026 г., 22:04 ч. UTC

Пазарно говорене

Oil Price Likely Lower, Equities Higher on Iran Deal Talks Progress -- Market Talk

23.05.2026 г., 08:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

23.05.2026 г., 08:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

22.05.2026 г., 21:10 ч. UTC

Печалби

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

22.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

22.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

22.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

22.05.2026 г., 19:47 ч. UTC

Печалби

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22.05.2026 г., 19:17 ч. UTC

Пазарно говорене

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22.05.2026 г., 19:10 ч. UTC

Пазарно говорене

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22.05.2026 г., 18:54 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

22.05.2026 г., 18:54 ч. UTC

Пазарно говорене

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22.05.2026 г., 18:38 ч. UTC

Пазарно говорене

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22.05.2026 г., 18:35 ч. UTC

Придобивния, сливания и поглъщания

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22.05.2026 г., 18:09 ч. UTC

Пазарно говорене

Centralized Crypto Lending Slows in 1Q -- Market Talk

22.05.2026 г., 17:58 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Anavex Life Sciences Corp Прогноза

Ценова цел

By TipRanks

640.74% нагоре

12-месечна прогноза

Среден 20 USD 640.74%

Висок 20 USD

Нисък 20 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Anavex Life Sciences Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на Anavex Life Sciences Corp през последните 3 месеца.

Настроение

By Acuity

325 / 345 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.